Europass
Curriculum Vitae
Personal information
First name(s) / Surname(s)
Elisa Gallerani
Address
Telephone(s)
E-mail(s)
Nationality
Date of birth
Gender
Italian
22/12/1973
Female
Occupational field Medical oncologist in Multimedica Castellanza Varese Italy
Work experience
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Dates
Main activities and responsibilities
Name and address of employer
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Dates
Occupation or position held
Page 1 / 7 - Curriculum vitae of
Elisa Gallerani
01/01/1995 - 01/01/1997
Training volunteer
Assistance in ambulance
Italian Red Cross
01/08/1997 - 31/08/1997
Clerkship
Training as medical student in the Internal Medicine and First Aid
Universitary Hospital
Linkoping (Sweden)
01/10/1997 - 31/12/1997
training as medical student
Radiotherapy Department
Bologna (Italy)
01/03/1998 - 30/03/1998
Elective
Medical student
Oncology Department
Odense (Denmark)
01/11/1998 - 30/12/1998
Post graduated internship
First Aid and Endocrinology Department
Odense (Denmark)
01/01/1999 - 01/01/2000
Junior fellow
For more information on Europass go to http://europass.cedefop.europa.eu
© European Union, 2002-2010 24082010
Main activities and responsibilities
Name and address of employer
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Medical doctor
Heamatology Department of the Hematology and Oncology Institute "L.A.Seragnoli", University
Hospital
Bologna (Italy)
01/01/2000 - 30/10/2000
Junior Fellow
Medical doctor
Oncology Department, University of Insubria, Ospedale di Circolo
Varese (Italy)
01/11/2000 - 30/09/2003
Junior Fellow
Medical doctor
Oncology Institute of Southern Switzerland, Ospedale Beata Vergine
Mendrisio (Switzerland)
01/10/2003 - 30/06/2006
Senior responsible
Medical responsible for outpatient clinic and oncology ward and clinical trials in phase I-II-III
Oncology Institute of Southern Switzerland, Ospedale San Giovanni
Bellinzona (Switzerland)
01/07/2006 - 23/12/2006
Fellowship
Clinical research fellow in phase I trials with experimental drugs in oncology
Royal Marsden Hospital , Drug Development Unit
Sutton (United Kingdom)
01/01/2007 - 15/07/2011
Senior responsible
Medical responsible for conducting phase I clinical trials with experimental drugs in oncology
Oncology Institute of Southern Switzerland, Ospedale San Giovanni
Bellinzona (Switzerland)
Dates
01/08/2011 →
Occupation or position held
Medical doctor
Main activities and responsibilities
Name and address of employer
Responsible of phase II/III trials and working in the clinic
Breast Unit, Ospedale Santa Maria Multimedica
Castellanza (Italy)
Education and training
Dates
Title of qualification awarded
Name and type of organisation
providing education and training
Dates
Title of qualification awarded
Name and type of organisation
providing education and training
Page 2 / 7 - Curriculum vitae of
Elisa Gallerani
15/10/1998 - 15/10/1998
Medical graduation (MD with honours)
Alma Mater Studiorum, Medical School, University of Bologna
Bologna (Italy)
01/10/2002 - 01/10/2002
Specialisation in Oncology
Oncology, University of Insubria
Varese (Italy)
For more information on Europass go to http://europass.cedefop.europa.eu
© European Union, 2002-2010 24082010
Dates
Title of qualification awarded
Name and type of organisation
providing education and training
Dates
Title of qualification awarded
20/10/2004 - 20/10/2004
Certificate for ESMO examination
European Society of Medical Oncology
Bern (Switzerland)
15/09/2006 - 15/09/2006
Certificate of ICH-GCP
Name and type of organisation
providing education and training
Royal Marsden Hospital
Sutton (United Kingdom)
Dates
13/03/2008 - 14/03/2008
Title of qualification awarded
Name and type of organisation
providing education and training
Dates
Title of qualification awarded
Teacher and moderator in ESO course on clinical research in oncology for nurses
SUPSI ( Scuola universitaria professionale della svizzera italiana)
Stabio (Switzerland)
01/12/2009 - 01/12/2009
Certificate of ICH-GCP e learning tool recognised by SWAPP/SGPM
Name and type of organisation
providing education and training
Dates
Title of qualification awarded
Principal subjects / occupational skills
covered
19/01/2010 - 19/01/2010
PhD in experimental oncology
Thesis: Phase I study of the oral platinum agent satraplatin (S) in sequential combination with
capecitabine (C) in patients with advanced solid tumors"
Name and type of organisation
providing education and training
University of Insubria
varese (Italy)
Level in national or international
classification
Pubblication in Acta Oncologica
Dates
Title of qualification awarded
Name and type of organisation
providing education and training
Dates
Title of qualification awarded
Name and type of organisation
providing education and training
Dates
Title of qualification awarded
Principal subjects / occupational skills
covered
Name and type of organisation
providing education and training
10/01/2011 - 10/01/2011
Certificate of ICH-GCP
Bellinzona (Switzerland)
16/06/2013
Certificate of ICH-GCP
Roche e learning tool
13/05/2011 - 13/05/2011
Invited speaker
Targeted therapy in oncology supported by AIOM ( Italian Society of Medical Oncology)
Milano (Italy)
Personal skills and
competences
Mother tongue(s)
Italian
Other language(s)
Self-assessment
Page 3 / 7 - Curriculum vitae of
Elisa Gallerani
Understanding
Speaking
For more information on Europass go to http://europass.cedefop.europa.eu
© European Union, 2002-2010 24082010
Writing
European level (*)
English
Listening
Reading
Spoken interaction
Spoken production
B1 Independent user B2 Independent user B2 Independent user B2 Independent user B2 Independent user
(*) Common European Framework of Reference (CEF) level
Social skills and competences
Computer skills and competences
Driving licence(s)
Additional information
Good skill working with different professional team
Competence with all microsoft programs
B
Posters and publications
- Tamberi S, Gallerani E, Bazzocchi R, Zompatori M, Martinelli G, Schiavina M, Di Marco MC, Brandi
G, Biasco G. Carboplatin (CBDCA) and paclitaxel (TAX) as induction chemotherapy in stage IIIA-IIIB
in non small cell lung cancer (NSCLC) Eur J Cancer 1999; 35:S4 Abstract 1052
- Di Marco MC, Mordenti P, Pantaleo MA, Gallerani E, Brandi G, Poggi B, Biasco G, Di Battista M.
The folfox4 regimen: a mono-institutional experience in advanced colorectal cancer Ann Oncol 12
S4:8, 2001
- Di Marco MC, Mordenti P, Pantaleo MA, Gallerani E, Brandi G, Poggi B, Biasco G, Di Battista M.
New therapeutic strategies in advanced colorectal cancer: our clinical experience Ann Oncol 12
S4:13, 2001 Abstract A43
- Biasco G, Gallerani E. Treatment of liver metasteses from colorectal cancer: what is the best
approach today? Digest Liver Dis 2001;33:438-44
- Romagnani E, Gallerani E, Cavalli F. Mediastinal mature teratoma with an immature component-what about the treatment? Ann Oncol. 2006 Oct;17(10):1602-4
- Gallerani E, Lerch E, Romagnani E, Stathis A, Giardelli G, Zwhalen H, Marone C, Cavalli F.
Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for
multiple myeloma successfully treated with rituximab. Eur J Haematol. 2006 Dec;77(6):527-9
- S. C. Pacey, R. Wilson, M. Walton, M. Eatock, J. Moreno-Farre, E. Gallerani, V. Davergne, F.
Raynaud, P. Workman. A phase I trial of the heat shock protein 90 (HSP90) inhibitor 17dimethylaminoethylamino-17-demethoxygeldanamycin (17- DMAG, alvespimycin) administered
weekly. J Clin Oncol, 2007 ASCO;25:18S Abstract 3568
- A. H. Reid, A. Tang, J. Spicer, E. Gallerani, D. Mears, S. Settatree, T. A. Yap, T. Puchalski, M.
Harrison, J. S. De-Bono. An open, pharmacokinetic (PK) and mass balance study of 14C-AZD2171,
incorporating DCE-CT evaluations. J Clin Oncol, 2007 ASCO;25:18S Abstract 14140
- E. Gallerani, T. A. Yap, A. Lopez, C. Coronado, H. Shaw, A. Florez, B. de las Heras, H. CortesFunes, J. de Bono, L. Paz-Ares Phase I study of PM00104, a novel cytotoxic anti-cancer drug,
administered to patients with advanced solid tumors or lymphoma. J Clin Oncol, 2007 ASCO;25:18S
Abstract 2517
- E. Van Cutsem, Y. Humblet, H. Gelderblom, J. B. Vermorken, F. Viret, B. Glimelius, F. Ciardiello, E.
Gallerani, N. Amellal, M. Peeters. Cetuximab dose-escalation study in patients with metastatic
colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment
(EVEREST): Pharmacokinetic and efficacy data of a randomized study. J Clin Oncol, 2007
ASCO;25:18S Abstract 237
- E. Gallerani, S. Cresta, D. Tosi, C. Sessa, G. Capri, C. V. Catapano, F. Bertoni, S. Marsoni, J. Tursi,
L. Gianni A phase I-II and pharmacodynamic (PD) study of the combination of the proteasome
inhibitor Bortezomib (B) and paclitaxel (P) in patients with taxane-sensitive solid tumors. J Clin Oncol,
2006 ASCO ;24:18S Abstract 13029
- O. Pagani, M. Ruggeri, T. Rusca, R. Graffeo, E. Gallerani, M. Locatelli, M. Conti Beltraminelli, S.
Longhi, L. Mazzucchelli, A. Goldhirsch Does HER2/neu expression affect adjuvant treatment choices
in routine clinical practice? J Clin Oncol, 2006 ASCO ;24:18S Abstract 10667
- A. Perotti, M. Maur, L. Viganò, E. Gallerani, R. Angst, J. Albanell, C. Sessa, R. Laliberte, S. Marsoni,
L. Gianni Phase Ib pharmacokinetic (PK) and pharmacodynamic (PD) study to define the optimal dose
for combining the mTOR inhibitor AP23573 with capecitabine (CAPE). J Clin Oncol, 2006 ASCO
;24:18S Abstract 3065
- F. de Braud, C. Sessa, E. Gallerani, G. Curigliano, C. Cipolla, A. Columbo, A. Gallino, G.
Schackleton, C. Zilocchi, M. Chadjaa Phase I dose escalation study of SR271425 administered as 24hour intravenous continuous infusion in patients with refractory solid tumors. J Clin Oncol, 2005 ASCO
Page 4 / 7 - Curriculum vitae of
Elisa Gallerani
For more information on Europass go to http://europass.cedefop.europa.eu
© European Union, 2002-2010 24082010
;24:18S Abstract 3116
- E.Gallerani, M.Ciriolo, C.Rossini, F.Cavalli. Axillary apocrine carcinoma with brain metastases. J Clin
Oncol. 2007 Dec 10;25(35):5655-6.
- C. Sessa, D. Hess, J. Bauer, C. Droege, E. Gallerani, M. Miani, A. Tinazzi, O. Krieter, R. Angst, C.
Nay. Phase I study of the oral platinum agent satraplatin (S) in sequential combination with
capecitabine (C) in patients with advanced solid tumours. J Clin Oncol.2008 Proc Am Soc Clin Oncol
(ASCO); Abstract 2560
- D. Hess, A. Delmonte, S. Boehm, E. Gallerani, P. Barbieri, P. Carminati, C. Pisano, E. Maccione, N.
Coceani, C. Sessa. Clinical development of ST1968, a novel camptothecin derivative with high
antitumor activity.Preclinical and preliminiary clinical data. ESMO 2008, 494P Poster
- C.Sessa, CV.Catapano, E.Gallerani, D.Passalacqua, A.Rinaldi, F.bertoni, L.Vigano’, M.Maur,
G.Capria, E.Maccioni, D.Tosi, L.Gianni. Phase I study of bortezomib with weekly paclitaxel in patients
with advanced solid tumours. Eur J Cancer. 2008,44:1829-34
- C.Sessa, A.perotti, C.Noberasco, F.De Braud, E.Gallerani, S.Cresta, M.Zucchetti, L.Vigano’,
A.Locatelli, J.Jimeno, J.W.Feilchenfeldt, M.D’Incalci, G.Capri, N.Ielmini, L.Gianni. Phase I clinical and
pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast
cancer. Eur J Cancer 2008, in press DOI: 10.1016/j.ejca.2008.11.019
- C. Sessa, D. Hess, J. Bauer, C. Droege, E. Gallerani, M. Miani, A. Tinazzi, O. Krieter, R. Angst, C.
Nay Phase I study of the oral platinum agent satraplatin (S) in sequential combination with
capecitabine (C) in patients with advanced solid tumours. J Clin Oncol 26: 2008 (May 20 suppl; abstr
2560)
- Gillessen S, Gallerani E, Beck J, Laurent J, Erpenbeck VJ, Speiser D, Templeton A, Gnad-Vogt U,
Sessa C, Stupp R. A phase I dose-escalation study with the modified IL-2/anti-DNA immunocytokine
EMD 521873 (Selectikine) in patients with advanced solid tumors: Preliminary results of safety,
pharmacokinetics, immunogenicity, and biological effects. AACR 2009, Poster
- D. Hess, S. Boehm, A. Delmonte, E. Gallerani, P. Barbieri, S. Pace, P. Carminati, S. Marsoni, N.
Coceani, C. Sessa. Clinical development of Namitecan (ST1968), a novel camptothecin derivative
with high antitumor activity: phase I clinical data. J Clin Oncol.2009 Proc Am Soc Clin Oncol (ASCO);
Abstract 2570
- M. C. Garassino, G. Michetti, M. Lo Dico, R. Califano, S. Aglione, K. Borgonovo, A. Mancuso, D.
Galetta, E. Gallerani, E. Collovà, V. Torri. Outcomes of small cell lung cancer (SCLC) patients treated
with second-line chemotherapy (SL): A retrospective analysis of 166 patients. J Clin Oncol 27, 2009
(suppl; abstr e19093)
- S. Cresta, C. Sessa, G. Del Conte, A. Locatelli, E. Gallerani, F. Fiorentini, A. Scaburri, M. A.
Pacciarini, R. Alzani, L. Gianni. Phase I study of the oral CDK-TRKA inhibitor PHA-848125
administered with prolonged schedules of administration. J Clin Oncol 28:7s, 2010 (suppl; abstr 3065)
- E. Gallerani, J. Delord, P. Schoffski, I. B. Vergote, V. N. Trillet-Lenoir, M. Maur, M. G. Jannuzzo, A.
Petroccione, G. Locatelli, D. Lorusso;Phase II study of danusertib (D) in advanced/metastatic breast
and ovarian cancers (BC, OC). J Clin Oncol 28:7s, 2010 (suppl; abstr 5014)
- Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E,
Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G,
Thatcher N, Blackhall F, Lorigan P, Califano R. Outcomes of small-cell lung cancer patients treated
with second-line chemotherapy: A multi-institutional retrospective analysis. Lung Cancer. 2010 Oct 13.
[Epub ahead of print]
- Gallerani E, Bauer J, Hess D, Boehm S, Droege C, Jeckelmann S, Miani M, Herrmann R, Marsoni S,
Sperka S, Sessa C. A phase I study of the oral platinum agent satraplatin in sequential combination
with capecitabine in the treatment of patients with advanced solid malignancies. Acta Oncol. 2010 Dec
27. [Epub ahead of print]
- S. Gross, V. Lennerz, E. Gallerani, C. Sessa, N. Mach, S. Boehm, D. Hess, L. von Boehmer, A.
Knuth, A. Ochsenbein, U. Gnad-Vogt, J. Zieschang, U. Forssmann, T. Woelfel, E. Kaempgen. First-inhuman trial focusing on the immunologic effects of the survivin-derived multiepitope vaccine
EMD640744. J Clin Oncol 29: 2011 (suppl; abstr 2515)
- A. Fasolo, G. Del Conte, R. G. Calderone, E. Gallerani, N. Hagner, P. Barbieri, L. Luraghi, S. Pace,
F. Capocasa, N. Coceani, E. Maccioni, D. Hess, C. Sessa, L. Gianni Phase I clinical trial of namitecan
(ST1968): Results with D1-3 q3wks schedule. J Clin Oncol 29: 2011 (suppl; abstr e13570)
- P. A. Cassier, V. Moreno Garcia, C. Gomez-Roca, D. Olmos, R. Morales, G. Del Conte, E. Gallerani,
A. Brunetto, P. Schoffski, S. Marsoni, J. H. M. Schellens, N. Penel, E. E. Voest, T. R. J. Evans, R.
Plummer, R. H. Wilson, J. Soria, J. Tabernero, J. Verweij, S. B. Kaye, European Drug Development
Page 5 / 7 - Curriculum vitae of
Elisa Gallerani
For more information on Europass go to http://europass.cedefop.europa.eu
© European Union, 2002-2010 24082010
Network; Dose-response relationship in phase I clinical trials: A European Drug Development Network
(EDDN) collaboration study. J Clin Oncol 29: 2011 (suppl; abstr 3084)
- C. Sessa, E. Gallerani, G. Del Conte, A. Christinat, A. Perotti, P. Lardelli, C. M. Kahatt, A. Florez, C.
Fernandez, M. Miani, L. Gianni. Phase I dose-finding study of trabectedin (T) in combination with
cisplatin (C) in patients (pts) with advanced solid tumors. J Clin Oncol 29: 2011 (suppl; abstr 2517)
- David Olmos, Roger P. A'Hern, Silvia Marsoni, Rafael Morales, Carlos Gomez-Roca, Jaap Verweij,
Emile E. Voest, Patrick Schöffski, Joo Ern Ang, Nicolas Penel, Jan H. Schellens, Gianluca del Conte,
Andre T. Brunetto, T.R. Jeffry Evans, Richard Wilson, Elisa Gallerani, Ruth Plummer, Josep
Tabernero, Jean-Charles Soria, and Stan B. Kaye Patient Selection for Oncology Phase I Trials: A
Multi-Institutional Study of Prognostic Factors J Clin Oncol Mar 20, 2012:996-1004
- Eric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, Marc Peeters, Yves Humblet, Hans
Gelderblom, Jan B. Vermorken, Frederic Viret, Bengt Glimelius, Elisa Gallerani, Alain Hendlisz,
Annemieke Cats, Markus Moehler, Xavier Sagaert, Soetkin Vlassak, Michael Schlichting, and
Fortunato Ciardiello Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer
According to the Grade of Early Skin Reactions: The Randomized EVEREST Study JCO Aug 10,
2012:2861-2868
-Gillessen S, Gnad-Vogt US, Gallerani E, Beck J, Sessa C, Omlin A, Mattiacci MR,
Liedert B, Kramer D, Laurent J, Speiser DE, Stupp R. A phase I dose-escalation study of the
immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer.
2013 Jan;49(1):35-44
-Laurent J, Touvrey C, Gillessen S, Joffraud M, Vicari M, Bertrand C, Ongarello S,
Liedert B, Gallerani E, Beck J, Omlin A, Sessa C, Quaratino S, Stupp R, Gnad-Vogt
US, Speiser DE. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an
IL-2/anti-DNA fusion protein. J Transl Med. 2013 Jan 7;11:5.
-Gallerani E, Cathomas R, Sessa C, Digena T, Bartosek AA, Dal Zotto L, von Moos R. A phase I study
of the oral platinum agent satraplatin in combination with oral vinorelbine in patients with advanced
solid malignancies. Onkologie. 2013;36(1-2):40-5
-Sessa C, Del Conte G, Christinat A, Cresta S, Perotti A, Gallerani E, Lardelli P,
Kahatt C, Alfaro V, Iglesias JL, Fernández-Teruel C, Gianni L. Phase I clinical and pharmacokinetic
study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
Invest New Drugs. 2013 Mar 7
-Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte
A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F,
D'Incalci M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in
patients with advanced solid tumours and multiple myeloma Eur J Cancer. 2013 Jan;49(2):290-6.
- Lennerz V(1), Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer
L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T,
Kaempgen E. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in
patients with advanced solid tumors. Cancer Immunol Immunother. 2014 Feb 2.
- Aurilio G1, Graffeo R, Bagnardi V, Nolè F, Adamoli L, Pagani O, Gallerani E, Ferrari B, Pruneri G,
Goldhirsch A. Estramustine phosphate sodium in heavily pretreated patients with metastatic breast
cancer: a retrospective consecutive case series. Int J Clin Oncol. 2014 Apr 12.
- Cassier PA1, Polivka V2, Judson I3, Soria JC4, Penel N5, Marsoni S6, Verweij J7, Schellens JH8,
Morales-Barrera R9, Schöffski P10, Voest EE11, Gomez-Roca C4, Evans TR12, Plummer R13, Gallerani
E14, Kaye SB3, Olmos D3. Outcome of patients with sarcoma and other mesenchymal tumours
participating in phase I trials: a subset analysis of a European Phase I database. Ann Oncol. 2014
Jun;25(6):1222-8.
- G Del Conte, C Sessa, R von Moos, L Viganò, T Digena, A Locatelli, E Gallerani, A Fasolo, A
Tessari, R Cathomas and L Gianni Phase I study of olaparib in combination with liposomal
doxorubicin in patients with advanced solid tumours British Journal of Cancer , (15 July 2014)
-Moreno García V1, Olmos D1, Gomez-Roca C2, Cassier PA1, Morales-Barrera R3, Del Conte G4,
Page 6 / 7 - Curriculum vitae of
Elisa Gallerani
For more information on Europass go to http://europass.cedefop.europa.eu
© European Union, 2002-2010 24082010
Gallerani E5, Brunetto AT6, Schöffski P7, Marsoni S8, Schellens JH9, Penel N10, Voest E11, Evans J12,
Plummer R13, Wilson RH14, Soria JC2, Tabernero J3, Verweij J15, Kaye SB Dose-Response
Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration
Study. Clin Cancer Res. 2014 Nov 15;20(22):5663-71
I CONDUCT CLINICAL TRIALS ACCORDING TO ICH-GCP.
HEREBY I AUTHORISE THE USE OF MY PERSONAL DATA IN COMPLIANCE WITH
LEGISLATIVE DECREE 196/2003.
Page 7 / 7 - Curriculum vitae of
Elisa Gallerani
For more information on Europass go to http://europass.cedefop.europa.eu
© European Union, 2002-2010 24082010